FONAR Corporation
NASDAQ:FONRMedical - Devices
+$0.00 today
- Market cap
- $117.76M
- Beta
- 0.95
- P/E (TTM)
- 17.6
- EPS (TTM)
- $1.08
Volume 0.00M
Average 0.08M
FONR EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
FONAR CorporationNASDAQ: FONR
EBITDA · Q3 FY2026 · quarter ended Mar 2026
EBITDA declines year over year
Q3 FY2026 EBITDA of $3.93M fell 26.9% year over year, behind the -15.8% change in trailing-twelve-month EBITDA. Sequentially, it fell 14.5% from the prior quarter. Over 3 fiscal years it compounded at -12.5% a year.
Context
- EBITDA amounted to 17.7% of revenue in FY2025, down 5.5 pp from a year earlier.
- EBITDA increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -26.9% toward the trailing-twelve-month pace of -15.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 18.5M USD
- Year-over-year change
- -22.7%
- 4-year CAGR
- -4.2%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-06-30 | 18.5M | -22.7% |
| FY2024 | 2024-06-30 | 23.94M | -2.7% |
| FY2023 | 2023-06-30 | 24.61M | -11.0% |
| FY2022 | 2022-06-30 | 27.65M | +25.7% |
| FY2021 | 2021-06-30 | 22M | — |
EBITDA vs competitors
How FONR compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -15.8% is the 7th highest of 8, against a peer median of +9.4%.
- EBITDA amounts to 15.1% of revenue for FONR, versus a peer median of 54.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $15.91M USD | -15.8% | -12.5% | 15.1% | |
| LTM Mar 2026 | -$2.44M USD | +81.8% | — | 4.4% | |
| LTM Mar 2026 | -$26.64M USD | -14.1% | — | — | |
| LTM Mar 2026 | -$33.15M USD | +15.7% | — | 216.2% | |
| LTM Mar 2026 | -$37.72M USD | +25.1% | — | 52.1% | |
| LTM Mar 2026 | -€42.36M EUR | +1.6% | — | 144435.8% | |
| LTM Mar 2026 | -$48.22M USD | +9.4% | — | 54.5% | |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | -$84.44M USD | -35.4% | — | — |
| Peer median (excluding FONR) | — | +9.4% | — | 54.5% | |
Competitors are the stored peer set for FONR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Jun 2021 | FY2022 Jun 2022 | FY2023 Jun 2023 | FY2024 Jun 2024 | FY2025 Jun 2025 |
|---|---|---|---|---|---|
| Revenue | 89.93M | 97.59M | 98.65M | 102.88M | 104.35M |
| Cost of Revenue | 46.46M | 50.58M | 52.9M | 57.74M | 61.44M |
| Gross Profit | 43.47M | 47.01M | 45.75M | 45.14M | 42.91M |
| Gross Margin | 48.3% | 48.2% | 46.4% | 43.9% | 41.1% |
| Research & Development | 1.64M | 1.49M | 1.57M | 1.74M | 1.58M |
| Selling, General & Admin | 0 | 0 | 29.39M | 0 | 29.73M |
| Operating Expenses | 26.38M | 25.01M | 30.96M | 28.6M | 31.31M |
| Depreciation & Amortization | 4.08M | 4.54M | 8.8M | 4.6M | 4.7M |
| EBITDA | 22M | 27.65M | 24.61M | 23.94M | 18.5M |
| EBITDA Margin | 24.5% | 28.3% | 25.0% | 23.3% | 17.7% |
| Operating Income | 17.1M | 22.01M | 14.79M | 16.54M | 11.6M |
| Operating Margin | 19.0% | 22.6% | 15.0% | 16.1% | 11.1% |
| Interest Income | 0 | 0 | 0 | 0 | 2.17M |
| Interest Expense | 248.67K | 346.55K | 50.13K | 77K | 25.61K |
| Other Income / Expenses | 567.72K | 761.69K | 969.33K | 2.73M | 2.18M |
| Income Before Tax | 17.67M | 22.77M | 15.76M | 19.27M | 13.78M |
| Pre-Tax Margin | 19.6% | 23.3% | 16.0% | 18.7% | 13.2% |
| Income Tax Expense | 3.99M | 5.53M | 3.63M | 5.17M | 3.11M |
| Net Income | 10.21M | 12.44M | 9.38M | 10.57M | 8.33M |
| Net Margin | 11.4% | 12.7% | 9.5% | 10.3% | 8.0% |
| EPS (Basic) | 1.47 | 1.78 | 1.35 | 1.56 | 1.26 |
| EPS (Diluted) | 1.45 | 1.75 | 1.32 | 1.53 | 1.23 |
| Weighted Avg Shares | 6.61M | 6.55M | 6.65M | 6.35M | 6.32M |
| Weighted Avg Shares (Diluted) | 6.74M | 6.68M | 6.77M | 6.48M | 6.55M |
FONAR Corporation
NASDAQ:FONR
Intrinsic Alpha fair value
Locked
Current Price
$19.09
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.